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DOI 10.1016/j.ccr.2011.12.026SUMMARYLymphatic metastasis is facilitated by lymphangiogenic growth factors VEGF-C and VEGF-D that are
secreted by some primary tumors. We identified regulation of PGDH, the key enzyme in prostaglandin catab-
olism, in endothelial cells of collecting lymphatics, as a key molecular change during VEGF-D-driven tumor
spread. The VEGF-D-dependent regulation of the prostaglandin pathway was supported by the finding
that collecting lymphatic vessel dilation and subsequent metastasis were affected by nonsteroidal anti-
inflammatory drugs (NSAIDs), known inhibitors of prostaglandin synthesis. Our data suggest a control point
for cancer metastasis within the collecting lymphatic endothelium, which links VEGF-D/VEGFR-2/VEGFR-3
and the prostaglandin pathways. Collecting lymphatics therefore play an active and important role in
metastasis and may provide a therapeutic target to restrict tumor spread.INTRODUCTION
The lethality of cancer is primarily associated with metastasis,
the spread of cancer cells from a primary site to distant organs
(Liotta, 1992). The spread of tumor cells to lymph nodes (LNs)
is an important prognostic indicator for disease staging, and
thus the lymphatic vasculature is considered a route of meta-Significance
The lymphangiogenic growth factor VEGF-D promotes canc
Elevated VEGF-D levels in human tumors correlate with lymp
nisms underlying lymphogenous spread to lymph nodes rema
draining primary tumors to sentinel lymph nodes identified a li
VEGF-D modulates prostaglandin levels to regulate collecting
key interaction between lymphangiogenic factors and prostagl
for tumor cell dissemination, and a mechanism by which NSA
vessels may therefore constitute a therapeutic target for preve
Cstatic spread (Achen and Stacker, 2008). However, it is note-
worthy that systemic metastasis can occur independently of
LN spread highlighting the complex nature of the process of
systemic disease (Sleeman et al., 2011).
Some tumors secrete lymphangiogenic growth factors that act
on the lymphatic vasculature to facilitate metastasis. These
factors can induce lymphangiogenesis, that is, the formation ofer spread via the lymphatics, a crucial step in metastasis.
h node metastasis and poor patient prognosis, yet mecha-
in elusive. Transcriptional profiling of collecting lymphatics
nk between VEGF-D-signaling and prostaglandin pathways.
lymphatic vessel dilation, an effect blocked by NSAIDs. This
andins reveals a mechanism for preparing collecting vessels
IDs reduce lymphogenous metastasis. Collecting lymphatic
ntion and treatment of metastatic disease.
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Figure 1. Lymphangiogenic Growth Factors Induce Collecting Lymphatic Vessel Dilation
(A) Representative image of the skin-flank 293EBNA tumor model, indicating primary tumor and the CLV (white dashed arrow) draining to the SLN.
(B and C) Representative images of flank skin containing the tumor-draining CLV stained for the lymphatic marker podoplanin, from mice bearing metastatic
VEGF-D-293EBNA tumors (B) and nonmetastatic 293EBNA tumors (C). A, artery; CLV, collecting lymphatic vessel (arrowheads in C); V, vein. Scale bars: 200 mm.
(D and E) Hematoxylin and eosin (H&E) staining of LNs containing afferent CLVs. A dilated afferent CLV (arrowhead) can be seen in a patient with VEGF-D-positive
metastatic breast carcinoma, (D) compared to a nonmetastatic control LN, which has a nondilated afferent collecting lymphatic (arrowhead) (E). CLV, collecting
lymphatic vessel. Scale bars: 100 mm.
(F) Representative images of flank skin highlightingCLVs (black arrows) frommice bearing nonmetastatic andmetastatic 66cl4mammary adenocarcinoma. Scale
bars: 1 mm.
(G) Quantitative analysis of CLV diameter inmice bearing nonmetastatic andmetastatic 66cl4mammary adenocarcinoma. Data aremean ± SEM; nR 5. *p < 0.05
by t test.
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PGs Regulate Metastasis in Collecting Lymphaticsnew lymphatics from preexisting vessels, in regions within or
immediately adjacent to, a primary tumor (Tammela and Alitalo,
2010). They can affect vessels beyond the tumor environ-
ment, such as those within the sentinel lymph node (SLN)
(Farnsworth et al., 2011) and can modulate immune responses
to the tumor (Tammela and Alitalo, 2010). Despite its clinical
implications, the mechanisms underpinning metastasis via the
lymphatic network are not well understood.
Lymphaniogenic growth factors include two vascular endo-
thelial growth factor (VEGF) family members, VEGF-C and
VEGF-D, which act through the cell surface-localized receptor
tyrosine kinases VEGFR-2 and VEGFR-3 (Joukov et al., 1996;
Achen et al., 1998; Ma¨kinen et al., 2001). There is a strong
association between elevated tumor expression of VEGF-C or
VEGF-D, increased tumor lymphatic vessel density and
enhanced rates of metastasis to LNs (Achen and Stacker, 2008).
The VEGF-C- or VEGF-D-signaling axes are pivotal in control-
ling lymphangiogenesis during cancer. Tumor models demon-
strate that inhibiting this signaling may block lymphogenous
cancer spread by restricting lymphatic vessel formation (Stacker
et al., 2001; He et al., 2005; Hoshida et al., 2006). In addition,
other VEGF-independent signaling pathways may operate in
lymphatic endothelial cells (LECs) or associated cells such as
mural cells or pericytes (Cao et al., 2004; Achen and Stacker,
2006).
The lymphatic network is a well-characterized hierarchy of
vessels, beginning as initial lymphatics in the superficial dermis
that drain into deep dermal precollecting lymphatic vessels,
which, in turn, drain into subcutaneous collecting lymphatic
vessels (CLVs) (Oliver and Alitalo, 2005). Individual lymphatic
vessel subtypes perform distinct, specialized functions; the
smaller initial lymphatics perform an absorptive role, whereas
precollector vessels guide lymph down to CLVs, a conduit to
the draining LN basin (Shayan et al., 2006). These features are
reflected in their respective morphologies. Unlike the initial
lymphatics, the CVLs have circumferential smooth muscle cells
(SMCs) and regular intraluminal valves to help propel a unidirec-
tional flow of fluid (Shayan et al., 2006).
Determining the step(s) in metastatic spread regulated by
lymphangiogenic growth factors is critical for developing optimal
therapeutic strategies to control metastasis. Recently, the focus
of much research has been to understand the mechanisms
underlying the effects of tumor-derived VEGF-C or VEGF-D
on initial lymphatics within and around the primary tumor
(Mandriota et al., 2001; Skobe et al., 2001; Stacker et al., 2001;
Bjo¨rndahl et al., 2005; Hoshida et al., 2006; Roberts et al.,
2006; Kopfstein et al., 2007). However, the influence of these
factors on lymphatic vessels distal to the primary tumor, for(H–K) Representative images of flank skin containing CLVs draining 293EBNA
nonmetastatic control (H) or VEGF-A-overexpressing tumors (I), or metastatic tu
(L) Quantitative analysis of CLV diameter in mice bearing 293EBNA nonmetastati
VEGF-D tumors. Data are mean ± SEM; nR 10. **p < 0.01 by t test.
(M and N) Representative images of flank skin highlighting collecting lymphatics
treated with an isotype control antibody (M) or VD1, a neutralizing antibody agai
(O) Quantitative analysis of CLV diameter in mice bearing nonmetastatic 293EBN
VD1. Data are mean ± SEM; nR 4. *p < 0.05 by t test.
(P) Quantification of the relative percentage of BrdU-positive nuclei per CLV in m
Data are the mean of six sections/mouse ± SEM; nR 3.
See also Figure S1.
Cexample, the CLVs draining the primary tumor to the SLN,
remains elusive. Historically, CLVs were considered passive
conduits that drain defined tissue areas to LNs (Sappy, 1874).
However, recent observations in tumor models of VEGF-C-
driven lymphogenous spread indicate that CLVs may play an
active role in metastasis by increasing lymph flow through vessel
dilation (He et al., 2005; Hoshida et al., 2006).
In this study, we investigated how CLVs are altered during
VEGF-D-driven metastasis and how the CLVs are prepared to
facilitate tumor spread.
RESULTS
Lymphangiogenic Growth Factors Induce Dilation
of Collecting Lymphatic Vessels
We examined the mechanism(s) by which VEGF-D could regu-
late CLVs that drain primary metastatic tumors using VEGF-
D-expressing tumor models (Figure 1A). Our xenograft model
of lymphogenous spread is based on the nonmetastatic
293EBNA cell line, which has negligible baseline expression of
VEGF family members (Figures S1A–S1D available online). Lym-
phogenous spread occurs when lymphangiogenic growth
factors are overexpressed (Stacker et al., 2001), allowing us to
examine any changes to collecting lymphatic vessels exposed
to tumor-secreted VEGF familymembers. Immunohistochemical
staining of skin sections containing the CLVs draining primary
VEGF-D-293EBNA metastatic tumors revealed them to be
dilated compared to the same vessels from the nonmetastatic
control animals (Figures 1B and 1C). The correlation between
VEGF-D and dilated collecting lymphatics could also be
observed in clinical specimens. The afferent CLVs were dilated
in a patient with VEGF-D-positive metastatic breast cancer
compared to the matched patient sample with nonmetastatic
breast cancer (Figures 1D and 1E; Figures S1E and S1F).
To examine the breadth of these findings, we assessed addi-
tional tumor cell lines for endogenous levels of VEGF family
members, in particular, VEGF-D. Expression analysis revealed
both breast cancer cell lines 66c14 and MDA-MB-435 express
endogenous levels of VEGF-D compared to other cell lines
such as the prostate tumor cell line PC3 and the poorly meta-
static breast cancer cell line MDA-MB-231 (Figures S1G–S1K).
Therefore, in addition to our VEGF-D-overexpressing 293EBNA
model, the 66c14 and MDA-MB-435 tumor cell lines were em-
ployed for subsequent manipulations.
We interrogated CLVs in our orthotopic model of breast
cancer involving 66cl4 mammary adenocarcinoma cells (Sloan
et al., 2010). This model of metastasis is associated with an
upregulation of vegf-A and vegf-D but not vegf-C within thetumors, highlighting collecting lymphatics (white arrowheads) from mice with
mors overexpressing VEGF-C (J) or VEGF-D (K) . Scale bars: 1 mm.
c or overexpressing VEGF-A tumors, or metastatic overexpressing VEGF-C or
(white arrowheads) from mice bearing metastatic VEGF-D-293EBNA tumors
nst VEGF- D (N). Scale bars: 1 mm.
A or metastatic VEGF-D-293EBNA tumors treated with an isotype control and
ice bearing nonmetastatic 293EBNA or metastatic VEGF-D-293EBNA tumors.
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Figure 2. Purification and Characterization of Collecting Lymphatic
Endothelial Cells
(A) Representative images of the microdissection procedure and a fully
dissected CLV following identification with Patent Blue V. The ruler depicted
indicates 1 mm graduation marks.
(B) Single-color flow cytometric analysis of unpurified single-cell suspension
prepared from CLVs, stained with podoplanin (green) or an isotype-matched
control (filled purple).
(C) Representative bright field image of unpurified cells following CLV harvest
and culture. Scale bar: 10 mm.
(D and E) Immunofluorescence of single-cell suspension culture from CLVs
stained for podoplanin (green) and SMC-actin (red). Scale bar: 50 mm. The
boxed area in (D) is a magnified area from the original image to highlight the
SMC-actin positive-staining cells and depicted as (E). Scale bar: 10 mm. Nuclei
were counterstained with DAPI.
(F–H) Immunofluorescence of the enriched podoplanin-positive cLEC fraction
fromCLVs. Cells were stained with podoplanin (green) and SMC-actin (red) (F),
LYVE-1 (green) (G) and Prox-1 (green) (H). Scale bars: 10 mm.
(I) Relative expression of lymphatic-specific genes following purification of
cLECs from CLVs analyzed by qRT-PCR. Gene expression was normalized to
b-actin. Data are mean ± SEM; nR 5.
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and subsequent LN and distant organ metastasis (Figures
S1L–S1N). Tracking of collecting lymphatics in mice bearing
66c14 breast tumors revealed that CLVs were dilated in animals
bearing metastatic tumors in which VEGF-D was upregulated,
compared to nonmetastatic controls (Figures 1F and 1G).
To ascertain the specific contribution of VEGF-D to collecting
lymphatic dilation, we utilized variants of the 293EBNA model
that overexpress VEGF-A, VEGF-C, or VEGF-D. When com-
pared to nonmetastatic controls, mice bearing metastatic
VEGF-D-expressing tumors had enlarged CLV diameters
(Figures 1H, 1K, and 1L) consistent with observations made
during VEGF-C-driven tumor spread (Figures 1J and 1L; He
et al., 2005). This dilation was reversed when mice bearing
VEGF-D tumors were treated with VD1, a neutralizing VEGF-D
antibody (Figures 1M–1O). Collecting lymphatic dilation was
not observed in mice bearing VEGF-A-expressing tumors
(Figures 1I and 1L), suggesting that VEGF-A has little effect on
collecting lymphatic dilation. Previous studies showed that
lymphatic vessels have the capacity to functionally adapt by
dilating in response to VEGF-C, and this was attributed to hyper-
plasia of the endothelium (Jeltsch et al., 1997; He et al., 2005).
In contrast, we found no significant increase in the number of
BrdU-positive endothelial cells in dilated collecting lymphatics
from mice bearing LN metastasis in VEGF-D-secreting tumors,
compared with nonmetastatic controls (Figure 1P; p = 0.327).
These data suggest that VEGF-D drives morphological changes
in CLVs that correlate with metastasis, and are not due to endo-
thelial cell proliferation.
Isolation and Characterization of Collecting Lymphatic
Endothelial Cells during Cancer Spread
To define the molecular mechanisms driving the morphological
changes in collecting lymphatics during metastasis, we devel-
oped a method to isolate CLVs draining primary tumors. Large
subcutaneous CLVs were visualized using Patent Blue V and
separated from blood vessels and surrounding skin tissue by
microdissection (Figure 2A).
LYVE-1 is strongly expressed on smaller caliber lymphatic
vessels, namely, the initial and precollector lymphatics, whereas
it is weakly expressed on collecting vessels (Ma¨kinen et al.,
2005). In contrast, podoplanin is expressed strongly on all
lymphatic vessel subtypes (Ma¨kinen et al., 2005), and podopla-
nin-positive selection was therefore used to isolate collecting
lymphatic endothelial cells (cLECs). Flow cytometry of cell
suspensions prepared from microdissected CLVs prior to purifi-
cation showed that approximately 75% of cells were positive for
podoplanin (Figures 2B and 2C) and immunofluorescence re-
vealed the presence of podoplanin-positive cells interspersed
with smooth muscle actin (SMA)-positive cells, a marker for
mural cells (Figures 2D and 2E). The presence of SMA is consis-
tent with in vivo observations of the association of mural cells
with CLVs (Ma¨kinen et al., 2005). To allow molecular character-
ization of cLECs, podoplanin-positive cells were isolated. Immu-
nofluoresence of the cLEC-enriched fraction revealed cells that
stained weakly for the lymphatic markers, LYVE-1 and Prox-1
(Kriehuber et al., 2001), and contaminating SMC were not de-
tected (Figures 2F–2H). The cLEC-enriched fraction was not
contaminated by immune cells, as indicated by negligible levels
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time (qRT)-PCR revealed expression of other lymphatic markers,
such as VEGFR-3 (Podgrabinska et al., 2002). In addition,
VEGFR-2, recently shown to be expressed on dermal microvas-
cular LECs (Podgrabinska et al., 2002), was expressed by cLECs
(Figure 2I). Other endothelial and LECmarkers such as Pecam-1,
VE-cadherin, and EphrinB2 (Kriehuber et al., 2001; Ma¨kinen
et al., 2005; Baluk et al., 2007) were also detected (Figure 2I).
Collectively, these data confirm the endothelial nature of the
purified cLEC population that can be used to investigate the
molecular pathways in collecting lymphatics necessary for tumor
spread.
Collecting Lymphatic Vessels Alter Their Gene
Signature during VEGF-D-Driven Metastasis
To understand the molecular mechanisms underlying morpho-
logical changes in CLVs, we compared the molecular signature
of cLECs harvested fromCLVs from animals with VEGF-D-driven
metastasis to that from animals with nonmetastatic disease
(Figure 3A). Whole-genome profiling revealed reproducible
gene expression patterns observed among replicates, and
distinct and unique molecular signatures that differentiated
between cLECs from animals with metastatic disease to those
with nonmetastatic tumors (Figure 3B).
Several key genes that were differentially expressed between
these groups could be arranged according to their cellular roles:
cell surface receptors, secreted factors, transcription factors
and cytoskeletal or extracellular matrix remodeling genes
(Figure 3C). The cell surface geneswere those important in adhe-
sion and inflammation; many of the secreted factors were also
modulators of inflammatory responses such as IL-11. Interest-
ingly, the majority of the differentially expressed genes fell into
the cytoskeletal or extracellular matrix modulatory group, which
is consistent with observation of dilated collecting lymphatics.
Within this gene group was pgdh, encoding 15-hydroxyprosta-
glandin dehydrogenase (PGDH), an enzyme whose key function
is degradation of prostaglandins (PGs), which are small lipid-
based molecules that can act as potent vasodilators. PGDH
was of interest as it has been identified as a tumor suppressor
in colorectal cancers (Myung et al., 2006).
The Tumor Suppressor, PGDH, Is Downregulated
in Collecting Lymphatics during VEGF-D-Driven
Metastasis
To validate differential pgdh expression levels, qRT-PCR was
employed, revealing a 20-fold reduction in the level of pgdh
gene expression in CLVs from metastatic VEGF-D-293EBNA
tumors compared to those draining nonmetastatic tumors (Fig-
ure 4A), consistent with the whole-genome profiling. To test for
the specificity of VEGF-D regulation of PGDH expression, we
evaluated the influence of the related lymphangiogenic factor,
VEGF-C, during metastasis. Collecting lymphatics from mice
bearing metastatic VEGF-C-293EBNA tumors did not reveal
a statistically significant change in pgdh expression (Figure 4A).
PGDH is a component of the catabolic arm of the PG pathway
whereas the COX proteins are key biosynthetic enzymes (Gupta
and Dubois, 2001). Studies have shown a correlation between
VEGF-C and COX-2 expression in metastatic cancers (Di et al.,
2009; Liu et al., 2010). To determine if VEGF-D could also regu-Clate the biosynthetic arm of the PGpathway, we assessed VEGF-
D regulation of cox-2 expression (Figure 4A). In contrast to the
VEGF-C control, VEGF-D had no effect on cox-2 levels in collect-
ing lymphatics (Figure 4A). To confirm the specific effect of
VEGF-D and to eliminate any possible effects of tumor-secreted
VEGF family members or other tumor factors on pgdh expres-
sion levels, cLECs harvested from nontumor bearing mice
were stimulated in vitro with VEGF-A, VEGF-C, or VEGF-D
(Figure 4B). qRT-PCR revealed that pgdh expression was not
altered by VEGF-A, in keeping with the lack of collecting
lymphatic dilation observed in our nonmetastatic VEGF-A-over-
expressing xenograft tumors (Figure 1L). Likewise, VEGF-C
stimulation in vitro had little effect on pgdh expression in cLECs.
Conversely, pgdh was significantly downregulated in cells
stimulated with VEGF-D compared with unstimulated control
cells (Figure 4B), suggesting that VEGF-D has a specific effect
on pgdh expression in cLECs.
We previously showed that cLECs express both VEGFR-2 and
VEGFR-3 (Figure 2I). To determine which of these receptors
mediates the downregulation of pgdh, selective blockade of
VEGFR-2 or VEGFR-3 was performed. VEGF-D stimulation of
cLECs following pretreatment with neutralizing antibodies
against VEGFR-2 or VEGFR-3 (Figures S2A and S2B) prevented
VEGF-D-induced downregulation of pgdh (Figure 4C).
Immunoblot analysis of cellular lysates prepared from CLVs
from mice bearing metastatic VEGF-D-293EBNA tumors
(Figure 4D) demonstrated that PGDH protein levels were down-
regulated. To assess the distribution and expression pattern of
PGDH with respect to lymphatic vessel subtypes, skin sections
containing major longitudinal CLVs from non-tumor-bearing
mice were stained with antibodies against PGDH. These showed
cytosolic protein expression in nondilated CLVs, the identity of
which was confirmed by positive staining with the lymphatic
marker, podoplanin (Figures 4E and 4H). In animals with VEGF-
D-driven metastatic disease, however, PGDH expression in the
dilated CLVs was reduced (Figures 4G and 4J) compared to
the CLVs in mice bearing nonmetastatic 293EBNA tumors
(Figures 4F and 4I). In combination with the microarray data,
these results suggest that VEGF-Dmediates the downregulation
of pgdh expression in dilated CLVs during VEGF-D-driven lym-
phogenous spread, and that this process requires the actions
of both VEGFR-2 and VEGFR-3.
VEGF-D/VEGFR-2/VEGFR-3-Signaling Axes Modulate
Prostaglandins Produced by Collecting Lymphatic
Vessels during Metastasis
To maintain homeostasis of PGs in tissues, there is a balance
between PG synthesis and degradation. We rationalized that
the downregulation of the PG degrading enzyme, PGDH, may
alter PG levels secreted by the collecting lymphatics, in partic-
ular PGE2, which is the main target for PGDH activity (Cha and
DuBois, 2007). Since the lymphatic vasculature eventually drains
into the circulatory system, we reasoned that local, continual
secretion of PGs by endothelial cells may be detected in the
plasma (Challis et al., 1976; Albuquerque et al., 2009). We tested
the plasma of mice exposed to VEGF-D for the PGs previously
shown to have vasodilatory effects (Olsson and Carlson, 1976;
Whorton et al., 1978) and found that PG levels, specifically
PGE2, in mice with VEGF-D-driven metastasis were elevatedancer Cell 21, 181–195, February 14, 2012 ª2012 Elsevier Inc. 185
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Figure 3. Collecting Lymphatic Vessels from Metastatic VEGF-D Tumors Have Distinct Gene Signature
(A) Schematic representation of experimental paradigm used to identify gene expression signatures in CLVs during VEGF-D-driven metastatic disease. This
involvedmicrodissection of the CLVs draining primary tumors to the SLN, purification of cLECs andmicroarray analysis (tumor cells: orange; collecting lymphatic
vessels and SLN: blue).
(B) Microarray analysis of cLECs isolated from mice bearing metastatic VEGF-D-293EBNA or nonmetastatic 293EBNA tumors from four independent experi-
ments. Data were visualized using Partek Genomics Suite software, by displaying a hierarchical cluster with average linkage analysis of normalized gene
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VEGF-A-secreting tumors (Figures S3A and S3B). A similar trend
regarding PGE2 was also observed in collecting lymphatic
tissues harvested from the same animals (Figure S3C). Next,
we assessed the ability of cLECs as an isolated cell type to
produce PGs in vitro and to determine whether there is a causal
relationship between VEGF-D signaling and modulation of PG
production by cLECs. Upon VEGF-D stimulation of cLECs, there
was an increase in PG levels (Figure 5A), further supporting the
notion that VEGF-D modulates tissue-specific PG production
by downregulating the PG degrading enzyme, pgdh (Figures
4A and 4B).
We endeavored to understand the VEGFR-2/VEGFR-3-
signaling mechanism necessary for VEGF-D-dependent PG
modulation by CLVs. Stimulation with VEGF-D led to phosphor-
ylation of VEGFR-2 in cLECs, which could be blocked by
pretreatment with neutralizing antibodies against either
VEGFR-2 or VEGFR-3 (Figure 5B). Likewise, phosphorylation
of VEGFR-3 was also blocked by both neutralizing antibodies
(Figure 5B), which is consistent with our observation that either
anti-VEGFR-2 or anti-VEGFR-3 antibody blocked the reduction
in PGDH expression induced by VEGF-D (Figure 4C). Next, we
assessed whether attenuation of VEGF-D signaling by blocking
VEGFR-2/VEGFR-3 activation would affect PG production by
cLECs. We found a significant reduction in PGs secreted by
cLECs that had been pretreated with either neutralizing anti-
VEGFR-2 or anti-VEGFR-3 antibodies (Figure 5C). Finally, we
investigated the effects of attenuating VEGF-D signaling in vivo
by blocking VEGFR-2 and VEGFR-3 activity, and hence PG
production by cLECs, on dilation of CLVs draining tumors.
CLVs in animals bearing metastatic VEGF-D-293EBNA tumors
treated with either VEGFR-2 or VEGFR-3 neutralizing antibodies
were not dilated (Figures 5D, 5E, and 5H) in contrast to dilated
collectors found in the isotype-treated and nonmetastatic
controls (Figures 5F–5H). Collectively, these data suggest that
VEGF-D—via the activities of both VEGFR-2 and VEGFR-3—is
able to regulate the levels of vasodilatory PGs produced by
collecting lymphatic vessel endothelium.
Anti-inflammatory Drugs Reduce VEGF-D-Driven
Metastasis by Reversing the Morphological Changes
in Collecting Lymphatic Vessels
The discovery that the lymphangiogenic molecule VEGF-D
modulates the morphology of collecting lymphatics via a
tissue-specific regulation of PG activity led us to investigate
whether pharmacologically manipulating this pathway would
reverse the effect of VEGF-D on metastasis. NSAIDs are a class
of commonly used analgesic and anti-inflammatory drugs and
are prototypical inhibitors of COX enzymes. To address whether
PGs contribute to ‘‘preparing’’ the collecting lymphatics that
drain the primary tumor for spread to the SLN, we sought to
shut down COX-2 and thereby ablate PG production. We
reasoned that a VEGF-D-mediated increase in PG production
by cLECs could be reduced concomitantly by inhibiting theexpression (>1.5-fold change, adjusted p values < 0.05). These data illustrate d
cLECs during metastatic disease compared to those from nonmetastatic tumor
(C) Selected genes whose expression was up- or downregulated in cLECs d
significance corresponds to p < 0.05 by HOLMS test.
Cbiosynthetic arm of the PG pathway by treatment with a COX-
2 inhibitor, Etodolac (Glaser et al., 1995). After testing the effi-
cacy of this drug in vitro (Figure S4A), we monitored its effects
on metastasis in the VEGF-D-293EBNA model. It has been
shown that NSAID treatment can reduce the levels of VEGFs
in some tumor models (Iwata et al., 2007), yet we found no
difference in plasma VEGF-D levels during NSAID treatment
(Figure S4B).
In addition, we employed the metastatic MDA-MB-435 breast
cancer model, which was shown to express endogenous VEGF-
D (Figures S1H–S1K). Primary tumor growth was not significantly
affected by NSAIDs in either VEGF-D-293EBNA or MDA-MB-
435 models (Figure 6A), in contrast to previous studies (Green-
hough et al., 2009).
The COX biosynthetic pathway has been shown to promote
metastasis by stimulating tumor-associated angiogenesis and
lymphangiogenesis (Iwata et al., 2007;Williams et al., 2000; Tsujii
et al., 1998). We found no significant difference in the density of
tumor-associated lymphatic or blood vessels between the
NSAID-treated and vehicle control groups in either VEGF-D-
293EBNA or MDA-MB-435 metastatic models (Figures 6B–6G;
Figures S4C–S4H). When we assessed dilation of collecting
lymphatics that drain the primary tumors in these models, we
found a compelling reduction in vessel diameter in NSAID-
treated mice in both tumor models (Figures 6I, 6L, and 6M)
compared with the nonmetastatic and vehicle control groups
(Figures 6H, 6J, 6K, and 6M). Cox-2-derived PGE2 promotes
tumor progression and metastasis and is significantly increased
in malignant tissue (Jaffe et al., 1971, Rigas et al., 1993). The
chemoprotective effects of NSAIDs are mediated by reducing
PGE2 levels (Hansen-Petrik et al., 2002). Treatment with
Etodolac significantly reduced PGE2 levels in both the VEGF-
D-293EBNA and the MDA-MB-435 breast cancer model, sug-
gesting that the dilation observed during metastasis may, in
part, be attributed to PGE2 (Figure 6N). PGs exert their biological
actions, such as vasodilation, by engaging specific receptors
(Amano et al., 2003). Protein expression of PGE receptors on
CLVs was found at low levels (Figure S4I), with a differential
expression pattern during metastasis and upregulation of EP3,
the receptor commonly engaged by PGE2 (Figure S4J).
To ascertain whether NSAID-mediated reversal of CLV dilation
affects metastasis, we examined the SLN (Kerjaschki et al.,
2011). In both the VEGF-D-EBNA293 andMDA-MB-435models,
we found a reduction of tumor cells in LNs from NSAID-treated
animals compared to the vehicle control (Figures 6O–6U).
Further, in the MDA-MB-435 model which displays systemic
metastasis to the lung, micrometastatic deposits in both the
pleural and subpleural area of lung sections could not be de-
tected in NSAID treated animals compared to those readily
observed in the vehicle control animals (Figures 6V and 6W; Fig-
ure S4K). NSAIDs have been shown to have antiproliferative,
proapoptotic, and antiangiogenesis effects (Cha and DuBois,
2007), yet we found no statistically significant differences in the
proliferation/apoptosis index or blood vessel density in LNsifferentially upregulated (red/orange) or downregulated genes (purple/blue) in
bearing mice. The gene expression patterns are consistent among replicates.
uring VEGF-D-driven metastatic disease in the 293EBNA model. Statistical
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Figure 4. VEGF-D Downregulates PGDH Expression in Collecting Lymphatic Vessels during Metastasis
(A) Real-time qPCR analysis of Pgdh and Cox-2 expression in cLECs harvested from mice bearing nonmetastatic 293EBNA or metastatic VEGF-C- or VEGF-
D-293EBNA tumors. Gene expression was normalized to b-actin. Data are mean ± SEM; nR 5. **p < 0.01 by t test.
(B) Real-time qPCR analysis of Pgdh expression in cLECs stimulated for 24 hr with VEGF-A (10 ng/ml), VEGF-C (100 ng/ml), and VEGF-D (100 ng/ml). Gene
expression was normalized to b-actin. Data are mean ± SEM; *p < 0.05 by t test.
(C) Real-time qPCR analysis of Pgdh expression in cLECs pretreated with neutralizing VEGFR-2 (DC101) or VEGFR-3 (mF4-31C1) antibodies before stimulation
with VEGF-D (100 ng/ml) for 24 hr. Data are mean ± SEM; *p < 0.05 by t test.
(D) Immunoblots of CLV lysates harvested from pools of mice bearing VEGF-D metastatic and nonmetastatic 293EBNA tumors, probed for PGDH. nR 5.
(E–J) Immunohistochemical staining of serial sections of flank skin containing collecting lymphatics (arrowheads) from non-tumor-bearing mice (E and H), or mice
bearing nonmetastatic 293EBNA (F and I), or metastatic VEGF-D-293EBNA tumors (G and J), stained for the cytosolic protein PGDH, or the lymphatic marker
podoplanin. Representative images are shown. Scale bars: 200 mm.
See also Figure S2.
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reduction of tumor cells in LNs of NSAID-treated animals was not
due to changes in proliferation, apoptosis, or angiogenesis
within the LN (Figures S4L and S4M) or primary tumor (data
not shown). Collectively, these data suggest that NSAIDs can
affect VEGF-D-regulated PG production by the collecting
lymphatic endothelium. This in turn may provide an antimeta-
static effect by preventing critical morphological alterations to
CLVs that are necessary to facilitate tumor cell spread to the
SLN (Figure 7).
DISCUSSION
Entry of tumor cells into the lymphatic system and subsequent
dissemination to LN and distant organ sites is an important event
in the metastasis of many solid tumors. In contrast to our knowl-
edge of the influence of lymphangiogenic factors on initial
lymphatics within and surrounding the primary tumor (Koukour-
akis et al., 2000; Pepper, 2001; Stacker et al., 2004; Sleeman and
Thiele, 2009), the effect of these factors on lymphatics beyond
the tumor environment is only beginning to emerge.
Isolation of endothelial cells from normal and tumor samples
has identified genes that are important during tumor-associated
angiogenesis and lymphangiogenesis (St Croix et al., 2000;
Clasper et al., 2008). We have isolated LECs from vessels
beyond the tumor microenvironment and have investigated the
molecular regulation that occurs in collecting lymphatics during
the metastatic process. Transcriptional profiling of cLECs from
CLVs draining metastatic VEGF-D-secreting tumors identified
gene signatures that are implicated in tissue remodeling and
inflammation. These studies found that VEGF-D regulates the
structure of the tumor-draining CLVs through a PG-dependent
mechanism, consistent with the elevated levels of inflammatory
mediators, such as PGs (Mantovani et al., 2008). In contrast,
tumor-associated initial lymphatics differentially expressed
genes encoding components of endothelial junctions, subendo-
thelial matrix, and vessel growth/patterning (Clasper et al., 2008).
Such variation between gene signatures may reflect the different
responses that lymphatic vessel subtypes exhibit to lymphan-
giogenic growth factors and the roles they perform during the
course of lymphogenous spread.
As an initial step toward evaluating mechanisms of metastasis
and potential therapeutic targets by which to restrict metastatic
disease, we focused on pgdh, which catalyzes the rate-limiting
step in the catabolism of PGs (Pichaud et al., 1997) and has
been identified as a tumor suppressor (Myung et al., 2006).
Endothelial-derived PGs are potent regulators of vasodilation,
attenuating or amplifying the response of blood vessels to
modulate vascular tone during normal and pathological states
(Messina et al., 1974; Gupta and Dubois, 2001). We extend this
finding to the CLVs, with ‘‘tissue-specific’’ regulation of PGs by
these vessels when exposed to VEGF-D. The importance of
PGDH during blood vessel dilation was initially demonstrated
in PGDH null mice, which have increased tissue PGE2 levels,
and as a consequence, a patent blood vessel shunt between
the lungs and heart, causing them to die soon after birth (Coggins
et al., 2002). It will be interesting to assess the lymphatic vascu-
lature in PGDH heterozygous mice during normal and patholog-
ical states.CPGs are produced in tissues by COX enzymes and levels are
balanced by the degrading activities of PGDH (Gupta and
Dubois, 2001). Clinically, high COX-2 expression in some tumors
is associated with poor patient prognosis and survival (Ristima¨ki
et al., 1997). The protumorigenic effects of COX-2 are believed to
be largely attributed to its role in synthesizing PGE2 (Pugh and
Thomas, 1994). Similarly, reduced PGDH expression and
a consequential rise in PGE2 levels enhance tumor growth in
colon, gastrointestinal, and breast cancers (Backlund et al.,
2005a; Backlund et al., 2005b;Wolf et al., 2006). Our data extend
this knowledge by demonstrating that reduced PGDH expres-
sion and elevated levels of PGE2 are important in lymphatic
endothelial cells beyond the tumor microenvironment, possibly
‘‘preparing’’ the CLVs to promote tumor spread.
It is not apparent at this stage whether lymphatic endothe-
lium-derived PGs act in an autocrine or paracrine manner to
modulate the overall tone of the CLVs during metastasis. The
actions of prostaglandins such as PGE2 are mediated by
engagement with their cognate receptors, EP1-4 (Greenhough
et al., 2009), with EP3 signaling shown to contribute to tumor
lymphangiogenesis (Kubo et al., 2010). In collecting lymphatics,
cLEC-derived PGs may activate SMCs associated with the
vessel walls; PG ligation of receptors on SMCs may induce
vessel wall relaxation to accommodate expansions in vessel
size (Tang and Vanhoutte, 2008). This effect is akin to that of
nitric oxide- and PG-dependent modulation of blood vessel
tone (Fukumura et al., 2006).
Lymphangiogenic growth factor modulation of PGs in CLVs is
mediated by both VEGFR-2 and VEGFR-3 signaling, possibly via
heterodimers. Recently published data showed that VEGF-D
stimulation of endothelial cells promotes the formation of
VEGFR-2/VEGFR-3 heterodimers (Nilsson et al., 2010). Consis-
tent with these findings, anti-VEGFR-2 or anti-VEGFR-3 thera-
peutic agents were shown to block CLV dilation, which corre-
lated with decreased lymph flow rates and consequently,
a reduction in the number of tumor cells reaching the SLN (He
et al., 2005; Hoshida et al., 2006). Based on data presented in
this study, it is feasible that the mechanism of metastatic
suppression by VEGFR-2 and VEGFR-3 blockade is, in part,
due to attenuation of PG levels in the collecting endothelium.
Since lymphatics are a conduit for immune cells, it cannot be
excluded that VEGF-D-induced dilation of collecting lymphatics
may contribute to metastasis by altering the traffic and behavior
of immune cells in the SLN, consequently modulating metastatic
burden.
NSAIDs are commonly used for the treatment of inflammatory
disease and can restrict the development of colon cancer
(Thun and Heath, 1995; Mantovani et al., 2008; Hirsch et al.,
2010) and tumor spread in breast and prostate cancer patients
(Holmes et al., 2010; Leitzmann et al., 2002), yet the precise
antimetastatic mechanism is unclear. Emerging evidence
suggests that COX-2 overexpression and high PGE2 levels are
associated with tumor angiogenesis and lymphangiogenesis,
processes crucial for metastasis (Iwata et al., 2007; Amano
et al., 2003; Tsujii et al., 1998). Recently, the effect of NSAIDs
on the lymphatic vasculature has been assessed within tumors,
where it was shown that treatment with a COX-2 inhibitor
reduced tumoral lymphangiogenesis, in turn, leading to
decreased metastasis to the SLN (Iwata et al., 2007). Evidenceancer Cell 21, 181–195, February 14, 2012 ª2012 Elsevier Inc. 189
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Figure 5. VEGF-D/VEGFR-2/VEGFR-3 Signaling Regulates Prostaglandins Produced by cLECs during Metastasis
(A) PG levels in supernatants of cLECs stimulated with VEGF-D (100 ng/ml) for up to 7 days. Assays were performed in triplicate. Data are mean ± SEM; *p < 0.05
by t test.
(B) VEGF-D-mediated activation of VEGFR-2 and VEGFR-3 in cLECs. cLECswere pretreated for 1 hr with neutralizing VEGFR-2 (DC101) or VEGFR-3 (mF4-31C1)
antibodies before stimulation with VEGF-D (100 ng/ml) for 10 min. VEGFR-2 and VEGFR-3 were immunoprecipitated from cLEC lysates and immunoblots were
probed for phosphorylation of VEGFR-2 and VEGFR-3.
(C) PG levels in supernatants of cLECs were measured by ELISA. cLECs were pretreated for 1 hr with neutralizing VEGFR-2 (DC101) or VEGFR-3 (mF4-31C1)
antibodies before stimulationwith VEGF-D (100 ng/ml) for up to 7days. Assayswere performed in triplicate.Data aremean±SEM; *p<0.05 and **p< 0.01 by t test.
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nism for the antimetastatic effects of NSAID treatment beyond
the tumor environment, one that involves normalizing the
diameter of CLVs that facilitate tumor cell trafficking to the
SLN (Figure 7B).
An emerging ‘‘subtypes-based’’ model for lymphogenous
spread suggests that lymphangiogenic growth factors have
two modalities. The first consists of proliferation or alteration of
tumor-associated initial lymphatics that enables tumor cells to
access to the lymphatic network (Figure 7A); the second involves
dilation of the CLVs beyond the tumor, which facilitates traf-
ficking to the SLN (Figure 7B). Understanding the functionally
important effects that VEGF-C and VEGF-D have on lymphatic
vessel subtypes may provide one of the missing links in the
metastatic process, and further refine our knowledge of the
complex nature of lymphogenous spread. These insights may
assist with the design of additional therapeutic avenues for
cancer patients and/or enhance current approaches to antilym-
phangiogenic therapies, such as blocking or neutralizing anti-
bodies in combination with other treatments such as NSAIDs.
EXPERIMENTAL PROCEDURES
Mice
Female SCID/NOD (IMVS, Adelaide, Australia) or Balb/c (ARC, Perth) mice
68 weeks of age were used for tumor studies and/or isolation of cLECs.
Ethics for approval for research using animals was obtained from the Ludwig
Institute for Cancer Research, Peter MacCallum Cancer Centre and Monash
University Animal Ethics Committees, in accordance with National Health
and Medical Research Council of Australia guidelines.
Human Tissue Specimens
Tissues were collected following surgical resection at the Peter MacCallum
Cancer Center. Ethics approval for research using human tissue was obtained
from the Peter MacCallum Cancer Centre (approval number 10/16) and
includes a waiver for consent. A tissue microarray from basal-like breast
carcinoma was constructed from a series of breast tumors screened for ER,
PR, HER2, EGFR, and cytokeratin 5 (ck5). Those tumors that were triple
negative (ER, PR, and her2) and ck5-positive and EGFR-positive were consid-
ered basal-type. 1 mm cores of tissue were punched from donor blocks.
Tissue microarrays were immunostained with anti-human VEGF-D antibody
(R&D Systems).
Metastatic and Nonmetastatic Xenograft Models
Stably transfected 293EBNA-1 cell lines expressing full-length human VEGF-D
(VEGF-D-293EBNA), human VEGF-C (VEGF-C-293EBNA) andmouse VEGF-A
(VEGF-A-293EBNA), vector alone (293EBNA), or MDA-MB-453-expressing
endogenous VEGF-D were established in SCID/NOD mice as described
(Stacker et al., 2001).
Orthotopic Metastasis Model
Six-week-old female Balb/c mice (ARC, Perth) were housed under PC2
barrier conditions. 66cl4 mammary adenocarcinoma cells were transduced
with the FUhlucW lentiviral vector containing firefly luciferase under control
of the ubiquitin-C promoter and were inoculated as previously described
(Sloan et al., 2010). See Supplemental Experimental Procedures for full
methods.(D–G) Representative images of CLVs filled with Patent Blue V from mice bear
(DC101) (D), VEGFR-3 (mF4-31C1) (E), or isotype control antibody (F) and nonm
(H) Quantification of CLV diameter in mice bearing nonmetastatic and metas
VEGFR-3 (mF4-31C1), or isotype control antibodies. Data are mean ± SEM; nR
See also Figure S3.
CTreatment of Tumors with Neutralizing Antibodies and NSAIDs
Mice bearing VEGF-D-expressing tumors received thrice weekly, beginning
5 days post-tumor inoculation, intraperitoneal injections of 800 mg of neutral-
izing anti-VEGFR-2 antibody (DC101; ImClone) or VD1 (Achen et al., 2000);
1 mg of neutralizing anti-VEGFR-3 antibody (mF4-31C1; ImClone); or isotype
matched antibody/PBS as vehicle control. For NSAID treatment, mice were
treated daily by oral gavage with 5 mg/kg of Etodolac (Sigma-Aldrich) (Iwata
et al., 2007) dissolved in 5% (w/v) carboxymethylcellulose, beginning 5 days
post-tumor inoculation and continued daily until tumors reached a size of
1,500–2,000 mm3 (typically 34 weeks).
Collection of tissue and isolation of cLECs used for various analyses
including immunohistochemistry, flow cytometry, BrdU analysis, prosta-
glandin assays, RNA purification, microarray analysis, and qRT-PCR are
described in detail in the Supplemental Experimental Procedures.
Harvest of Collecting Lymphatic Vessels
0.25% (w/v) Patent Blue V dye (Sigma-Aldrich) was injected postmortem into
hindlimb footpads of normal SCID/NODmice, or intratumorally in mice bearing
tumors, and massaged to promote uptake by the collecting lymphatics. Col-
lecting lymphatics thus identified were microdissected using a Zeiss OPMI
MDI dissecting microscope.
Isolation of Endothelial Cells from Collecting Lymphatic Vessels
Single-cell suspensions of cLECs were prepared by digestion of freshly
dissected CLVs with a cocktail of Blendzyme III (Roche) and DNase (Sigma-
Aldrich) for 1.5–2 hr at 37C. Cells were either seeded on fibronectin (5 mg/ml;
Sigma-Aldrich)-coated dishes for in vitro expansion, or subjected to immunoi-
solation by MACS (Miltenyi Biotec) using rabbit anti-mouse podoplanin anti-
body (30 mg/ml, Sigma-Aldrich). See Supplemental Experimental Procedures
for full method.
Flow Cytometry and Immunofluorescence
See Supplemental Experimental Procedures for full method.
Immunoprecipitation and Western Blotting
See Supplemental Experimental Procedures for full methods.
Immunohistochemistry and BrdU Incorporation
Mouse tissues were fixed in 4% paraformaldehyde before paraffin embedding
for analysis. See Supplemental Experimental Procedures for full methods.
RNA Isolation and Microarray Analysis
RNA was isolated using the RNeasy kit as per manufacturer’s instructions
(QIAGEN). See Supplemental Experimental Procedures for full methods.
Quantitative PCR
See Supplemental Experimental Procedures for a list of primers.
Quantification and Statistical Analysis
Images were quantified using Metamorph software. Student’s t test (Minitab
for Windows, MiniTab Inc) and HOLMS test were used for statistical analyses
where indicated.
ACCESSION NUMBERS
Microarray data were deposited in NCBI’s Gene Expression Omnibus; series
accession number GSE34135. (http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE34135).ing metastatic VEGF-D-293EBNA tumors treated with neutralizing VEGFR-2
etastatic tumor control (G). Scale bars: 1 mm.
tatic VEGF-D-293EBNA tumors treated with neutralizing VEGFR-2 (DC101),
4. **p < 0.01 by t test.
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Figure 6. NSAIDs Reverse Collecting Lymphatic Vessel Dilation during Metastatic Disease and Suppress Tumor Spread
(A) Measurement of subcutaneous VEGF-D-293EBNA and MDA-MB-435 tumors in mice undergoing treatment with NSAID, (Etodolac). Data are presented as
mean tumor volume (mm3) ± SEM. Tumor volumes are shown as a function of time (in days); nR 6.
(B–F) Immunohistochemical staining for the lymphatic marker LYVE-1 from mice bearing metastatic VEGF-D-293EBNA (B and C) and MDA-MB-435 (E and F)
tumors treated with NSAID (B and E), vehicle (C and F), or nonmetastatic 293EBNA tumor control (D). Arrows indicate vessels. Representative images are
depicted. Scale bars: 200 mm.
(G) Tumoral lymphatic vessel density (LYVE-1) in VEGF-D-293EBNA and MDA-MB-435 breast tumors frommice treated with either NSAID or the vehicle control.
Data are the mean of three sections/mouse ± SEM; nR 6.
(H–L)Macroscopic appearance of CLVs filledwith Patent Blue V frommice bearingmetastatic VEGF-D-293EBNA tumors (H and I) orMDA-MB-435 breast tumors
(K and L) treated with either vehicle (H and K) or NSAID (I and L), compared to the nonmetastatic 293EBNA tumor control (J). Scale bars: 1 mm.
(M) Diameter of CLVs in mice bearing metastatic VEGF-D-293EBNA or MDA-MB-435 breast tumors treated with either NSAID or vehicle. Data are mean ± SEM;
nR 6. *p < 0.05 and **p < 0.01 by t test.
(N) PGE2 levels in plasma from mice bearing metastatic VEGF-D-293EBNA or MDA-MB-435 breast tumors treated with either NSAID or vehicle. Assay was
performed in triplicate. Data are mean ± SEM; nR 5. *p < 0.05 by t test.
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A B
Figure 7. Schematic Overview of VEGF-D Effects in Tumor Metastasis
VEGF-D secreted by tumor cells promotes LN metastasis by (A) facilitating entry of tumor cells into initial lymphatics and (B) altering CLV dilation to facilitate
transit of tumor cells to the SLN. This is modulated by downregulation of PGDH, resulting in high levels of PGs secreted by cLECs as depicted in (I). Inhibitors
targeting the VEGF-D/VEGFR-2/VEGFR-3 or PG pathways in cLECs are likely to reduce PG levels and thereby restore vessel tone, suppressing metastasis as
shown in (II).
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